AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11039005 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular-plaster therapy plus acupuncture at Zusanli (ST 36)
Number of subjects: 26
Study 11039005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 18
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous administration of moxisylyte without a tourniquet
Number of subjects: 18
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous administration of moxisylyte with a tourniquet
Number of subjects: 18
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.v. administration
Number of subjects: 18
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.c. administration without a tourniquet
Number of subjects: 18
Study 8721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.c. administration with a tourniquet
Number of subjects: 18
Study 1443353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1-g single dose 30 minutes before surgery)
Number of subjects: 273
Study 1443353 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1-g dose 30 minutes before surgery and 1 g every 6 hours for 24 hours, total dose 4 g)
Number of subjects: 273
Study 1443353 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1-g dose 30 minutes before surgery, followed by 1 g every 8 hours for 48 hours, total dose 6 g)
Number of subjects: 273
Study 1443353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and Cefazolin
Number of subjects: 273
Study 3904673 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester antimicrobial incise drape (loban 2 Antimicrobial Film) with one-minute skin preparation using 70% alcohol or 2% iodine in 90% alcohol
Number of subjects: 1324
Study 3904673 — intervention group
Group type: COMPARATOR
Intervention: Standard ten-minute skin preparation with Betadine
Number of subjects: 1324
Study 31679112 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunercept plus reirradiation (rRT)
Number of subjects: 0
Study 31679112 — intervention group
Group type: COMPARATOR
Intervention: Reirradiation (rRT) alone
Number of subjects: 0
Study 29244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 1,200/600 mg
Number of subjects: 104
Study 29244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir (all groups)
Number of subjects: 104
Study 29244026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 27062157 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing (control)
Number of subjects: 10
Study 27062157 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 18% O2
Number of subjects: 10
Study 27062157 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 14% O2
Number of subjects: 10
Study 27062157 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 12.5% O2
Number of subjects: 10
Study 27062157 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution (Low [Hb])
Number of subjects: 10
Study 25080605 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH with home visit (LAUNCH-HV)
Number of subjects: 33
Study 25080605 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH-clinic
Number of subjects: 33
Study 25080605 — intervention group
Group type: COMPARATOR
Intervention: Pediatrician counseling (PC)
Number of subjects: 33
Study 22486142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ketamine
Number of subjects: 45
Study 22486142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of morphine (control)
Number of subjects: 45
Study 20360429 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic low-dose aspirin (81 mg)
Number of subjects: 10
Study 20360429 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic clopidogrel (75 mg)
Number of subjects: 10
Study 20360429 — intervention group
Group type: COMPARATOR
Intervention: No systemic drug (ND)
Number of subjects: 10
Study 20360429 — intervention group
Group type: COMPARATOR
Intervention: Localized COX inhibition (ketorolac)
Number of subjects: 10
Study 20360429 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide synthase inhibition (NOS-I)
Number of subjects: 10
Study 20360429 — intervention group
Group type: COMPARATOR
Intervention: NOS-I+COX-I
Number of subjects: 10
Study 20360429 — intervention group
Group type: COMPARATOR
Intervention: Time to increase Tor 1 degrees C
Number of subjects: 10
Study 18622831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 vol% 3-acryloyloxypropyltrimethoxysilane + 0.3 vol% 1,2-bis-(triethoxysilyl)ethane
Number of subjects: 20
Study 18622831 — intervention group
Group type: COMPARATOR
Intervention: Cimaratrade mark silane (control)
Number of subjects: 20
Study 18622831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 vol% 3-acryloyloxypropyltrimethoxysilane + 0.1 vol% 1,2-bis-(triethoxysilyl)ethane
Number of subjects: 20
Study 17954642 — intervention group
Group type: EXPERIMENTAL
Intervention: CT venography (CTV)
Number of subjects: 711
Study 17954642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CT venography (CTV) and CT angiography (CTA)
Number of subjects: 711
Study 17954642 — intervention group
Group type: COMPARATOR
Intervention: Combined CT angiography (CTA) and sonography
Number of subjects: 711
Study 17954642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with signs or symptoms of DVT
Number of subjects: 711
Study 17954642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of DVT
Number of subjects: 711
Study 15650347 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment protocol for HIV/STI prevention study
Number of subjects: 217
Study 11302304 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg sodium hyaluronate
Number of subjects: 226
Study 11302304 — intervention group
Group type: COMPARATOR
Intervention: physiologic saline (control)
Number of subjects: 226
Study 11302304 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Number of subjects: 226
Study 11302304 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 226
Study 9288374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen via a facemask at 4 l/min
Number of subjects: 100
Study 9288374 — intervention group
Group type: COMPARATOR
Intervention: No oxygen
Number of subjects: 100
Study 8323999 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (BC-PS) 300 mg/day for 6 months
Number of subjects: 494
Study 8323999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 3521254 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas I and V providing 13 g protein and 350 kcal per day
Number of subjects: 3
Study 3521254 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented group (control)
Number of subjects: 3
Study 30803326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice bag)
Number of subjects: 22
Study 30803326 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (room-temperature bag)
Number of subjects: 22
Study 30236308 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2661
Study 30236308 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2661
Study 27537244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 28
Study 27537244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24398818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and bupivacaine combinations
Number of subjects: 300
Study 22382053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 187
Study 22382053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) with Shared Decision Making intervention
Number of subjects: 187
Study 22382053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 187
Study 18980622 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO-depleted autografts
Number of subjects: 53
Study 18980622 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated autografts
Number of subjects: 53
Study 17617270 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine) 200 mg twice daily
Number of subjects: 612
Study 17617270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 17617270 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine)
Number of subjects: 612
Study 15204275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min nap during post-lunch rest period
Number of subjects: 8
Study 15204275 — intervention group
Group type: COMPARATOR
Intervention: No nap during the no-nap week
Number of subjects: 8
Study 15204275 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up week where subjects determined whether or not to nap
Number of subjects: 8
Study 11756100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1 mol/L) injected IV at doses of 0.1 or 0.3 mmol/kg
Number of subjects: 11
Study 11756100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1 mol/L) injected IV
Number of subjects: 11
Study 9690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer (up to three 26-day courses)
Number of subjects: 780
Study 9690266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (up to three 26-day courses)
Number of subjects: 780
Study 8015129 — intervention group
Group type: EXPERIMENTAL
Intervention: English version of the manuscript
Number of subjects: 180
Study 8015129 — intervention group
Group type: COMPARATOR
Intervention: National-language version of the manuscript
Number of subjects: 180
Study 8015129 — intervention group
Group type: EXPERIMENTAL
Intervention: Referee experience
Number of subjects: 180
Study 8015129 — intervention group
Group type: EXPERIMENTAL
Intervention: Referee age
Number of subjects: 180
Study 8015129 — intervention group
Group type: EXPERIMENTAL
Intervention: Referee gender, specialty, or nationality
Number of subjects: 180
Study 8015129 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-text comments
Number of subjects: 180
Study 2660319 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA).
Number of subjects: 40
Study 2660319 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA) in patients receiving OAC.
Number of subjects: 40
Study 31776061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified OK lens design (Test) with reduced back optic zone diameter and altered asphericity and intermediate lens curves.
Number of subjects: 16
Study 31776061 — intervention group
Group type: COMPARATOR
Intervention: Standard OK lens design (Control).
Number of subjects: 16
Study 31136070 — intervention group
Group type: COMPARATOR
Intervention: Zero dose of antibiotic prophylaxis (ABP)
Number of subjects: 426
Study 31136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ABP (30 min before surgery)
Number of subjects: 426
Study 31136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of ABP (first dose at 30 min before RIRS and additional dose within 6 h after RIRS)
Number of subjects: 426
Study 31136070 — intervention group
Group type: COMPARATOR
Intervention: Zero dose of ABP
Number of subjects: 426
Study 31136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ABP
Number of subjects: 426
Study 31136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of ABP
Number of subjects: 426
Study 28553988 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous acetaminophen
Number of subjects: 59
Study 28553988 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous acetaminophen
Number of subjects: 59
Study 28553988 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg intravenous acetaminophen
Number of subjects: 59
Study 28553988 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 59
Study 26624214 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Mediterranean dietary intervention
Number of subjects: 11
Study 23648697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-gluten diet (16 g gluten/d)
Number of subjects: 37
Study 23648697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-gluten diet (2 g gluten/d and 14 g whey protein/d)
Number of subjects: 37
Study 23648697 — intervention group
Group type: COMPARATOR
Intervention: Control diet (16 g whey protein/d)
Number of subjects: 37
Study 23648697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten diet (16 g/d)
Number of subjects: 37
Study 23648697 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey diet (16 g/d)
Number of subjects: 37
Study 23648697 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional protein)
Number of subjects: 37
Study 21605502 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI evening meal
Number of subjects: 14
Study 21605502 — intervention group
Group type: COMPARATOR
Intervention: Low-GI evening meal
Number of subjects: 14
Study 19701463 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity hypoventilation syndrome (OHS)
Number of subjects: 53
Study 17446974 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based psychotherapies for substance use disorder (SUD)
Number of subjects: 428
Study 14978601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training (400 Kcal, 15 g protein, 50% of vitamin DRVs per day, two sessions per week)
Number of subjects: 101
Study 14978601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training
Number of subjects: 101
Study 14978601 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation only
Number of subjects: 101
Study 14978601 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only
Number of subjects: 101
Study 14978601 — intervention group
Group type: COMPARATOR
Intervention: Control group (without supplementation nor training)
Number of subjects: 101
Study 15288708 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of AND (0.00625 M) in women
Number of subjects: 60
Study 15288708 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of AND (0.00625 M) in men
Number of subjects: 60
Study 10665519 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension (Azopt) t.i.d. in addition to timolol 0.5% b.i.d.
Number of subjects: 132
Study 10665519 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d. in addition to timolol 0.5% b.i.d.
Number of subjects: 132
Study 10665519 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% t.i.d.
Number of subjects: 132
Study 10665519 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 132
Study 9046703 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior management program with written cuing procedures implemented by trained caregivers during 12 weekly home visits.
Number of subjects: 14
Study 9046703 — intervention group
Group type: COMPARATOR
Intervention: Behavior tracking by matched control caregivers.
Number of subjects: 14
Study 9046703 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior management program with written cuing procedures.
Number of subjects: 14
Study 8443029 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril up to 20 mg
Number of subjects: 40
Study 8443029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol up to 100 mg
Number of subjects: 40
Study 8443029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol up to 100 mg in combination with hydrochlorothiazide 25 mg
Number of subjects: 40
Study 8443029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3097384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (1 tablet Euglucon N) + Insulin infusion (22 U human insulin/patient for 45 min)
Number of subjects: 8
Study 3097384 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Insulin infusion (22 U human insulin/patient for 45 min)
Number of subjects: 8
Study 3097384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide + Insulin infusion
Number of subjects: 8
Study 29893947 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings Coping Together intervention (n=41)
Number of subjects: 75
Study 29893947 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=34) with games and crafts only
Number of subjects: 75
Study 26799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CS) combined with topical agents
Number of subjects: 60
Study 26799345 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CS) monotherapy
Number of subjects: 60
Study 24764674 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole therapy (20 mg esomeprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Number of subjects: 0
Study 24764674 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole therapy (30 mg lansoprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Number of subjects: 0
Study 24764674 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole therapy
Number of subjects: 0
Study 24764674 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole therapy
Number of subjects: 0
Study 22435741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (various dose sizes) without MAOI‐A
Number of subjects: 0
Study 22435741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (various dose sizes) with MAOI‐A
Number of subjects: 0
Study 22435741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral almotriptan
Number of subjects: 0
Study 22435741 — intervention group
Group type: COMPARATOR
Intervention: MAOI‐A
Number of subjects: 0
Study 20804366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue acupuncture (40 sessions over 8 weeks)
Number of subjects: 50
Study 20804366 — intervention group
Group type: COMPARATOR
Intervention: Sham tongue acupuncture to nonacupoints in the tongue
Number of subjects: 50
Study 18184934 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified version of a habit reversal treatment (awareness training, self-monitoring, competing responses, and social support)
Number of subjects: 1
Study 16415708 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25 to 200 mg/d)
Number of subjects: 28
Study 16415708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14636088 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week plyometric training program
Number of subjects: 38
Study 14636088 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week plyometric training program
Number of subjects: 38
Study 10577699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy (CHART) - 36 fractions of 1.5 Gy 3 times per day to give 54 Gy in 12 consecutive days
Number of subjects: 563
Study 10577699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy (CHART)
Number of subjects: 563
Study 10577699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy (CHART) in squamous cell cancer
Number of subjects: 563
Study 8918509 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group sessions and free nicotine supplementation (patches, chewing gum)
Number of subjects: 400
Study 8918509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 1801964 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg)
Number of subjects: 16
Study 1801964 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg)
Number of subjects: 16
Study 6863583 — intervention group
Group type: EXPERIMENTAL
Intervention: experimenter-administered time-out of fixed duration
Number of subjects: 33
Study 6863583 — intervention group
Group type: EXPERIMENTAL
Intervention: experimenter-administered time-out of duration determined by the subject
Number of subjects: 33
Study 6863583 — intervention group
Group type: EXPERIMENTAL
Intervention: self-initiated time-out of fixed duration
Number of subjects: 33
Study 31125092 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg SC Q6M (long-term)
Number of subjects: 4074
Study 31125092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover)
Number of subjects: 4074
Study 27862923 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in TacER dose with targeted TacER trough level (C0) >3 μg/L (Group A)
Number of subjects: 186
Study 27862923 — intervention group
Group type: COMPARATOR
Intervention: No change in TacER dose (TacER C0 7-12 μg/L) (Group B)
Number of subjects: 186
Study 25760561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (LDCT) screening
Number of subjects: 1264
Study 25760561 — intervention group
Group type: COMPARATOR
Intervention: Control (yearly clinical review only)
Number of subjects: 1264
Study 24322192 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupuncture (Group I)
Number of subjects: 0
Study 24322192 — intervention group
Group type: COMPARATOR
Intervention: Non-specific acupuncture (Group II)
Number of subjects: 0
Study 21299874 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion
Number of subjects: 875
Study 18834718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-inducing mental session
Number of subjects: 54
Study 18834718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-inducing physical session
Number of subjects: 54
Study 17267907 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive end‐of‐life conference and brochure
Number of subjects: 126
Study 17267907 — intervention group
Group type: COMPARATOR
Intervention: Customary end‐of‐life conference
Number of subjects: 126
Study 15063379 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of the instructor giving the lecture
Number of subjects: 0